First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-07

Study Completion Date

2023-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is the first-in-human study of 68Ga/64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

NCT05930457

Malignant Solid Tumors

COMPLETED PHASE1

68Ga-NI-FAPI PET/CT: First-in-human Study

NCT06688305

Malignant Neoplasm

RECRUITING EARLY_PHASE1

68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer

NCT06084767

Malignant Tumor Positron Emission Tomography Fibroblast Activation Protein Inhibitor

RECRUITING NA

First Human Trial of Targeting MDM2/MDMX PET Imaging

NCT06443762

MDM2/MDMX Gene Mutation Nuclear Medicine Positron Emission Tomography Imaing

COMPLETED EARLY_PHASE1

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

NCT05637034

Tumor, Solid

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

20 patients with confirmed diagnosis of malignant solid tumor by histopathology or clinical judgment and required routine 18F-FDG PET/CT imaging were recruited. 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient in any order(the interval was more than one day and less than four weeks). They were assigned to three 68Ga/64Cu-FAPI-XT117 dose groups, including 3±10% mCi、5±10% mCi and 7 ±10% mCi. PET/CT images were acquired 30min, 60min, 120min after injection. The primary end point was safety, secondary endpoints were accuracy (AC), sensitivity (SE), specificity (SP), positive predictive value (PPV), and change in management. Exploring end point was image quality, including qualitative and quantitative evaluation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

68Ga/64Cu-FAPI-XT117 PET/CT

Each patient will receive 2-4 mCi, 4-6 mCi or 6-8 mCi 68Ga/64Cu-FAPI-XT117 intravenously (IV), and then PET/CT scanning within the specified time. On another day, patients receive 18F-FDG and then undergo PET/ CT.

Group Type EXPERIMENTAL

2-4 mCi 68Ga/64Cu-FAPI-XT117

Intervention Type DRUG

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.

4-6 mCi 68Ga/64Cu-FAPI-XT117

Intervention Type DRUG

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.

6-8 mCi 68Ga/64Cu-FAPI-XT117

Intervention Type DRUG

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2-4 mCi 68Ga/64Cu-FAPI-XT117

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.

Intervention Type DRUG

4-6 mCi 68Ga/64Cu-FAPI-XT117

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.

Intervention Type DRUG

6-8 mCi 68Ga/64Cu-FAPI-XT117

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. signed the informed consent
* 2\. ≥18 years old
* 3\. confirmed as malignant solid tumor by histopathology or clinical judgment
* 4\. Patients will undergo 18F-FDG PET/CT examination

Exclusion Criteria

* 1\. Known allergy to components of the investigational drug or its analogues
* 2\. suspected to have a certain disease or condition that is not suitable for the study drug
* 3\. Known pregnant or lactating women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No